Medical cannabis R&D startup Kanabo Research comes out of stealth mode with game changing, trusted formulations and vaporization solutions for the medical industry.
Avihu Tamir, CEO of Kanabo Research, presents his new venture’s pioneering technologies in medically validated extraction formulations and drug device combinations at this year’s CannaTech Innovation Summit, Israel’s premier international conference for showcasing cannabis technology, taking place in Tel Aviv, March 20-21, 2017.
With years of hands-on experience in multiple cannabis ventures and management consultancies for large corporations, Tamir founded Teva Nature, Israel’s leading vaporizer company. Through his latest venture, Kanabo Research, Tamir applies his experience to Israel’s burgeoning cannabis industry, working together with leading industry professionals, including Kanabo’s Scientific Director, pharmaceuticals veteran Dr. Doron Friedman, who has authored more than 80 granted patents and 20 peer-reviewed published articles. Kanabo is developing five unique patent-pending medical cannabis formulations for treating Central Nervous System disorders, for use solely with Kanabo’s medically validated vaporizer platform. Kanabo identified a US-based vaporizer company and manufacturing partner, and has modified their standard vaporizer to be a (patent-pending) medically validated device called the VapePodTM vaporizer.
“When I was prescribed medical cannabis to help treat my migraines, I was directed to smoke my prescription, which seemed ridiculous, as smoking is detrimental to one’s health,” says Avihu. “Oral intake of cannabis has a lower bioavailability and a slower onset than inhaling cannabis. As the market will soon be regulated, we wanted to launch a medically validated vaporizer together with clinically validated formulations that are designed to work synergistically.”
Last month, an Israeli government committee took the first steps toward advancing legislation to allow export of medical cannabis products, which should encourage new investment and innovation in the field. Kanabo is perfectly positioned to leverage this opportunity and target its medically validated VapePodTM vaporizer and precise formulations to all markets where medical cannabis is legal, including parts of North and South America, certain Western European countries, South Africa, and Australia.
This year’s CannaTech, powered by iCAN: Israel Cannabis, sees the convergence of pharmaceutical and cannabis industries with experts like Dr. Doron Friedman presenting about their recent medical cannabis activities. Tamir is coordinating a young cannabis entrepreneurs panel for the event, and will discuss how creation, risk-taking, and passion drives entrepreneurial success stories.
Tamir adds, “CannaTech has proven to be the most innovative industry event in the world. The uniqueness of Israel’s cannabis industry, the nation’s startup mentality, and the conference’s role as host to the world’s leading researchers is creating a new wave of IP-focused medical cannabis companies in this country, many of which I hope to share ideas with at the event.”